Vancomycin in an elderly patient with worsening renal function: reading a trough and rebuilding the dose
A 78-year-old woman (68 kg) was admitted with MRSA bacteraemia arising from an infected diabetic foot ulcer. Baseline serum creatinine was 1.3 mg/dL; it is now 1.8 mg/dL, giving an estimated creatinine clearance of about 33 mL/min by Cockcroft–Gault. She received a vancomycin loading dose of 1,500 mg on day 1 and has since been on 1,000 mg IV every 24 hours. Concomitant therapy includes piperacillin–tazobactam 4.5 g every 8 hours (renally adjusted), furosemide 40 mg daily and insulin. On day 4, a level drawn at 07:30, immediately before the fourth dose, is reported as 28 mg/L. Urine output is 0.6 mL/kg/h. The infectious-disease resident asks you whether the dose can simply be continued, saying "the trough is a bit high but she is a big lady". Blood cultures drawn yesterday are still negative; the patient is afebrile but has gained 3 kg since admission.
1. Interpret the 28 mg/L level against current vancomycin monitoring standards, judge whether the exposure target for MRSA bacteraemia is met, and list the data you still need before recommending a change.
Read the worked answer
What the number represents. Current guidance (ASHP/IDSA/PIDS/SIDP 2020) for MRSA with MIC ≤1 mg/L targets AUC24/MIC 400–600 and prefers AUC-guided dosing; trough-only monitoring is a fallback. So the correct question is not "is the trough 15–20?" but "what AUC does this trough imply?".
Why this trough is interpretable anyway. With a 24-hour interval and an elimination half-life of roughly 20–24 hours in this degree of renal impairment, the concentration–time curve is nearly flat, so the trough approximates the average steady-state concentration. Sanity-check it: CL ≈ 0.75 × CrCl ≈ 25 mL/min ≈ 1.5 L/h; AUC24 = daily dose ÷ CL = 1,000 ÷ 1.5 ≈ 670 mg·h/L; average concentration = 670 ÷ 24 ≈ 28 mg/L. The assay and the arithmetic agree, which means exposure is above the 400–600 window (AUC/MIC ≈ 670 with MIC 1.0).
Before acting, confirm: exact sampling time relative to end of infusion; that the sample was not drawn from the infusion line; infusion duration (should be ≥60 minutes); body weight and dosing weight (68 kg, not obese, so actual weight is appropriate); the reported MIC; and that day 4 represents steady state (about four half-lives - acceptable). Also confirm the creatinine trend, because falling clearance will keep pushing exposure up.
2. Recommend a specific new regimen and a monitoring plan, showing the arithmetic you used.
Read the worked answer
Target and calculation. Aim for AUC24 ≈ 500, mid-window. Daily dose = target AUC × CL = 500 × 1.5 L/h ≈ 750 mg per 24 hours. So: vancomycin 750 mg IV every 24 hours, infused over at least 60 minutes (2 hours is reasonable in a fragile elderly patient to limit infusion reactions).
No new loading dose is needed - the volume of distribution has not changed; the patient is already at steady state and over-exposed. A reload would simply prolong the excess.
Monitoring plan.
- Draw a trough immediately before the third dose of the new regimen (48–72 hours), aiming for roughly 15–20 mg/L, which is what an AUC of 400–600 looks like on a 24-hour interval when half-life is long.
- If the institution has Bayesian/AUC software, obtain two levels (near peak and trough) and calculate AUC24/MIC directly; this is more reliable than a single trough.
- Recheck serum creatinine and urine output daily. If CrCl falls below about 20 mL/min, move to 750 mg every 48 hours or 500 mg every 24 hours.
- Watch for red-man infusion reactions; slow the rate rather than reducing the dose.
- Reassess at 48–72 hours with cultures and clinical status; do not extend therapy beyond the ID plan simply because levels look convenient.
3. The creatinine has risen from 1.3 to 1.8 mg/dL. How do you assess and act on this, and how do you communicate it?
Read the worked answer
Staging. KDIGO stage 1 AKI is met by a rise of ≥0.5 mg/dL within 48 hours; her 0.5 mg/dL rise satisfies that even though the ratio (1.8/1.3 = 1.38) does not reach 1.5×. Urine output 0.6 mL/kg/h is above the <0.5 mL/kg/h oliguria threshold, so the output criterion is not yet met - but it is a trend to follow, not reassurance to file away.
Differential. Vancomycin at excessive exposure; the vancomycin–piperacillin–tazobactam association reported repeatedly in observational studies (confounded, but clinically actionable when vancomycin levels are high); sepsis and hemodynamics; furosemide with occult volume depletion - note the 3 kg weight gain, which makes "dry weight" elastic and may be fluid overload rather than tissue gain.
Actions. Do not stop vancomycin: she has MRSA bacteraemia and source control is the priority. Instead correct exposure as above, review whether piperacillin–tazobactam is still needed, and if gram-negative cover is required discuss cefepime (dose-adjusted, watch for neurotoxicity) or meropenem with ID. Avoid NSAIDs, contrast and aminoglycosides; chart strict fluid balance and daily weights.
Communication. Speak to the resident and the ID consultant directly, and write a dated pharmaceutical-care note naming the dose change, the rationale, the monitoring plan and the review time. Silent dose changes create duplicate orders and are a patient-safety hazard.